Many studies have shown that high TMB in tumours results in a better therapeutic effect with anti-PD-1/PD-L1 immunotherapy, including in some lung cancers [69], but there is no definitive validation for the use of this immunotherapy in clinical practice. Here, PDCD1 is linked to lung carcinoma.